Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Seligson

Showing results (181-190 of 195) with videos related to

Pageof 20
Sort By:
Clinical Orthopaedics and Related Research|October 1, 1993
Comparison of the clinical efficacy and tolerance of gentamicin PMMA beads on surgical wire versus combined and systemic therapy for osteomyelitisJ D Blaha, J H Calhoun, C L Nelson, et al.
Frontiers in Pharmacology|January 23, 2024
<i>CYP3A5</i> influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantationNathan D Seligson, Xunjie Zhang, Mark C Zemanek, et al.
NPJ Precision Oncology|April 26, 2022
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomasNathan D Seligson, Joy Tang, Dexter X Jin, et al.
Pharmacogenomics|July 29, 2025
From bench to bedside: a spotlight on pharmacogenomics at Nemours Children's HealthKelsey J Cook, Nathan D Seligson, Benjamin Q Duong, et al.
Cancers|November 9, 2024
Correction: Nelson et al. <i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> 2021, <i>13</i>, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Cancers|April 3, 2021
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Haematologica|March 2, 2023
<i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplantMelissa Thomas, Junan Li, Kevan King, et al.
Clinical and Translational Science|July 7, 2023
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institutionKelsey J Cook, Victoria Grusauskas, Lucy Gloe, et al.
Clinical Pharmacology and Therapeutics|July 13, 2021
Key Considerations for Selecting a Genomic Decision Support Platform for Implementing PharmacogenomicsKelsey J Cook, Benjamin Q Duong, Nathan D Seligson, et al.
Thyroid : Official Journal of the American Thyroid Association|June 6, 2022
Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter TrialNaifa L Busaidy, Bhavana Konda, Lai Wei, et al.
Pageof 20

Showing results (181-190 of 195) with videos related to

Sort By:
Pageof 20
Clinical Orthopaedics and Related Research|October 1, 1993
Comparison of the clinical efficacy and tolerance of gentamicin PMMA beads on surgical wire versus combined and systemic therapy for osteomyelitisJ D Blaha, J H Calhoun, C L Nelson, et al.
Frontiers in Pharmacology|January 23, 2024
<i>CYP3A5</i> influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantationNathan D Seligson, Xunjie Zhang, Mark C Zemanek, et al.
NPJ Precision Oncology|April 26, 2022
Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomasNathan D Seligson, Joy Tang, Dexter X Jin, et al.
Pharmacogenomics|July 29, 2025
From bench to bedside: a spotlight on pharmacogenomics at Nemours Children's HealthKelsey J Cook, Nathan D Seligson, Benjamin Q Duong, et al.
Cancers|November 9, 2024
Correction: Nelson et al. <i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. <i>Cancers</i> 2021, <i>13</i>, 1566Ryan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Cancers|April 3, 2021
<i>UGT1A1</i> Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical ImplementationRyan S Nelson, Nathan D Seligson, Sal Bottiglieri, et al.
Haematologica|March 2, 2023
<i>PARP1</i> and <i>POLD2</i> as prognostic biomarkers for multiple myeloma in autologous stem cell transplantMelissa Thomas, Junan Li, Kevan King, et al.
Clinical and Translational Science|July 7, 2023
Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institutionKelsey J Cook, Victoria Grusauskas, Lucy Gloe, et al.
Clinical Pharmacology and Therapeutics|July 13, 2021
Key Considerations for Selecting a Genomic Decision Support Platform for Implementing PharmacogenomicsKelsey J Cook, Benjamin Q Duong, Nathan D Seligson, et al.
Thyroid : Official Journal of the American Thyroid Association|June 6, 2022
Dabrafenib Versus Dabrafenib + Trametinib in <i>BRAF</i>-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter TrialNaifa L Busaidy, Bhavana Konda, Lai Wei, et al.
Pageof 20